Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection

Hepatology Research

Volumn 46, Issue 6, 2016, Pages 552-558

  Cao, Ying ^a   Zhang, Yu ^a   Bao, Yi ^b   Zhang, Renwen ^a   Zhang, Xiaxia ^a   Xia, Wei ^c   Wu, Hao ^c   Xu, Xiaoyuan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Shiyan Taihe Hospital   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis C virus; HIV hepatitis C virus co infection; Non structural 3 protease inhibitor; Resistance mutation

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS C; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEPATITIS C VIRUS SUBTYPE 1B; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; NS3 GENE; PRIORITY JOURNAL; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION;

EID: 84955304727     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12590     Document Type: Article

References (33)

1. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013 57: 1333-42.
2. Bennett H, Waser N, Johnston K et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int 2015 9: 378-90.
3. Qian HZ, Vermund SH, Kaslow RA et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 2006 20: 1429-35.
4. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014 348: g3308.
5. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014 146: 1669-79.
6. Organization WH. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization, 2014.
7. Miura M, Maekawa S, Sato M et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res 2014 44: E360-7.
8. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000 81: 1631-48.
9. Bartels DJ, Sullivan JC, Zhang EZ et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013 87: 1544-53.
10. Aissa LJ, Trimoulet P, Recordon-Pinson P et al. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol 2014 86: 1350-9.
11. Jabara CB, Hu F, Mollan KR et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother 2014 58: 6079-92.
12. Piroth L. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol 2011 35(Suppl 2): S75-83.
13. Bai L, Feng ZR, Lu HY, Li WG, Yu M, Xu XY. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 2009 122: 5-9.
14. Peres-da-Silva A, de Almeida AJ, Lampe E. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 2010 155: 807-11.
15. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013 207(Suppl 1): S33-9.
16. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010 2010-02-01;138: 447-62.
17. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol 2013 19: 8940-8.
18. Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 2012 9: 245.
19. Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010 54: 1878-87.
20. Sarrazin C, Lathouwers E, Peeters M et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015 116: 10-6.
21. Itakura J, Kurosaki M, Takada H et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res 2015 Jan 6. doi: 10.1111/hepr.12474. [Epub ahead of print]
22. Lontok E, Harrington P, Howe A et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015 Jun 10. doi: 10.1002/hep.27934. [Epub ahead of print]
23. Leggewie M, Sreenu VB, Abdelrahman T et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013 27: 2485-8.
24. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014 384: 403-13.
25. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014 384: 414-26.
26. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014 146: 1669-79.
27. Bartels DJ, Sullivan JC, Zhang EZ et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013 87: 1544-53.
28. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009 51: 106-8.
29. Lisboa-Neto G, Noble CF, Pinho JR et al. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Antivir Ther 2015 20: 281-7.
30. Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009 137: 795-814.
31. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009 51: 106-8.
32. Franco S, Tural C, Nevot M et al. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. Gastroenterology 2014 147: 599-601.
33. Martin TC, Martin NK, Hickman M et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013 27: 2551-7.